Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia
Most Cited Paper
in Immunotherapy and Immune Responses
18 Months Post-Publication
Class of 2026
“Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/immunotherapy-and-immune-responses/2026/
Topics
Obecabtagene autoleucel · Obecabtagene autoleucel · CD19 CAR T-cell therapy · CAR T-cell therapy · intermediate-affinity CAR · relapsed or refractory B-cell acute lymphoblastic leukemia · morphologic disease · Minimal residual disease (MRD) · overall remission · complete remission with incomplete hematologic recovery · event-free survival · cytokine release syndrome · immune effector cell-associated neurotoxicity syndrome · Duration of response · CAR T cell persistence
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Immunotherapy and Immune Responses Papers, Class of 2026. https://pri.pepkio.com/top-papers/immunotherapy-and-immune-responses/2026. Accessed 2026-07-20. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459